 The main advantages of the proposed approach will: 1 Overcome the challenges in bone morrowperipheral blood stem cell PBSC collection in patients heavily pre-treated andor bonebone marrow infiltration with tumor. 2 Eliminate the risk of graft contamination with tumor cells, and 3 Graft-versus-tumor effect GVT to eliminate residual disease after conditioning chemotherapy. The use of allografting with the proposed regimen combines the benefits of high dose chemotherapy and an immune approach to disease therapy. 